| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disord... |
| 14 Oct 2026 |
8-K: Other Events
On October 14, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing plans to initiate an open-label extension (“OLE”) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotr... |
| 05 Oct 2026 |
8-K: Other Events
On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating ... |
| 15 Sep 2026 |
8-K: Other Events
On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100th) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302,... |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neu... |
| 07 Aug 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of Coya Therapeutics, Inc. (the “Company”) dated March 29, 2026 and filed with the Securities and Exchange Commission on April 2... |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 25 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 25, 2026, Coya Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were: (i) the election of two Class I directors and (ii) the ratificatio... |
| 13 May 2026 | ARS |
| 13 May 2026 | DEFA14A |
| 13 May 2026 | Proxy statement: annual meeting on June 25, 2026 |
| 12 May 2026 |
8-K: Entry into a Material Definitive Agreement
Coya Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 12 May 2026 | 424B5 |
| 12 May 2026 | 10-Q |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
HOUSTON, TX., May 12, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurod... |
| 09 Apr 2026 |
Form 4: Pavao Mark H, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Apr 2026 |
Form 3: Pavao Mark H, Director
No securities owned |
| 02 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Separation and General Release Agreement (“Agreement”) confirms the terms of the separation of Howard Berman’s (“you” or “your”) employment with Coya Therapeutics, Inc. (the “Company”), including the consideration described below in... |
Loading...